Item 5. Other Information
Item 5. Other Information.
On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the payment of retention bonuses of $56,000 to John Liatos and $41,250 to Steve Rychnovsky. The retention bonuses will be payable on the first business payment cycle following the end of our 2021 fiscal year, or earlier upon Board discretion.
On February 11, 2021, upon recommendation by the Compensation Committee, the Board approved the modification of the Company’s vacation policy from an accrual-based policy to an unlimited policy, which eliminates the need for an accounting liability for accrued vacation.
46
Item 6 . Exhibits.
10.1
First Amended Executive Employment Agreement, by and between Kintara Pharmaceuticals, Inc. and Saiid Zarrabian (incorporated by reference to Exhibit 10.1 to the Company’s quarterly report on Form 10-Q filed with the SEC on November 12, 2020)†
31.1
Certification of principal executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
31.2
Certification of principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 *
32.1
Certification of principal executive officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
32.2
Certification of principal financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 **
EX-101.INS
XBRL Instance Document *
EX-101.SCH
XBRL Taxonomy Extension Schema Document *
EX-101.CAL
XBRL Taxonomy Extension Calculation Linkbase *
EX-101.DEF
XBRL Taxonomy Extension Definition Linkbase *
EX-101.LAB
XBRL Taxonomy Extension Labels Linkbase *
EX-101.PRE
XBRL Taxonomy Extension Presentation Linkbase *
*
Filed herewith
**
Furnished herewith
†
Exhibit is a management contract or compensatory plan or arrangement.
47
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Kintara Therapeutics, Inc.
Date: February 12, 2021
By:
/s/ Saiid Zarrabian
Saiid Zarrabian
Chief Executive Officer
(Principal Executive Officer)
Date: February 12, 2021
By:
/s/ Scott Praill
Scott Praill
Chief Financial Officer
(Principal Financial and Accounting Officer)
48
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.